Latest Breaking News On - Takeda pharmaceutical company limited - Page 1 : comparemela.com

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 rADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura cTTP

Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval under exceptional circumstances of recombinant ADAMTS13 rADAMTS13 for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.

United statesKremer hovingaJun saitoVan dorlandThromb haemostTakeda pharmaceutical company limitedExchange commissionJapanese ministry of healthEuropean medicines agencyEuropean commissionTreatment optionsDrug administrationEuropean unionFranchise global program leader at takedaCommittee for medicinal products human usePotentially fatal blood clotting disorder

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK (BUSINESS WIRE) Jun 1, 2024

United statesJohn cunninghamJun saitoPeter borchmannExchange commissionAmerican society of clinical oncologyInternational mediaUniversity hospital of cologneImportant safety information european unionInternational agency for research on cancerHealth canadaEuropean unionTakeda pharmaceutical companyGerman hodgkin study groupTakeda pharmaceutical company limitedEuropean hematology association

Gold Investment Management Ltd Makes New $994,000 Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Gold Investment Management Ltd. acquired a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 69,664 shares of the company’s stock, valued at approximately $994,000. A number of other large investors […]

New yorkUnited statesYork state common retirement fundSecurities exchange commissionGold investment management ltdDorsey whitney trustPinnacle wealth planning services incTakeda pharmaceutical companyTakeda pharmaceutical company limitedAdvisor groupJp morgan private wealth advisorsGold investment managementFree reportTakeda pharmaceuticalWealth planning servicesPrivate wealth advisors

ASKA Pharmaceutical : May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area

Press Release Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area TOKYO, May 31, 2024 -.

Chuo kuMinato kuSohta yamaguchiCorporate planning departmentTakeda pharmaceutical company limited head officeHoldings co ltdCo ltdHead officePress releaseRelugolix combination tabletGynecologic disease areaTakeda pharmaceutical company limited

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesKremer hovingaVan dorlandThromb haemostFranchise global program leader at takedaJapanese ministry of healthEuropean unionTakeda pharmaceutical company limitedDrug administrationEuropean commissionExchange commissionEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useObi umeh